ZA200301427B - Valproic acid derivatives for the treatment of pain. - Google Patents
Valproic acid derivatives for the treatment of pain. Download PDFInfo
- Publication number
- ZA200301427B ZA200301427B ZA200301427A ZA200301427A ZA200301427B ZA 200301427 B ZA200301427 B ZA 200301427B ZA 200301427 A ZA200301427 A ZA 200301427A ZA 200301427 A ZA200301427 A ZA 200301427A ZA 200301427 B ZA200301427 B ZA 200301427B
- Authority
- ZA
- South Africa
- Prior art keywords
- effective dose
- pain
- amount
- therapeutically effective
- prophylactically effective
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 76
- 230000036407 pain Effects 0.000 title claims description 71
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical class CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title description 14
- 238000011282 treatment Methods 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims description 65
- 208000004296 neuralgia Diseases 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 208000021722 neuropathic pain Diseases 0.000 claims description 24
- 208000027109 Headache disease Diseases 0.000 claims description 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
- -1 carboxybenzyl Chemical group 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
- 230000000737 periodic effect Effects 0.000 claims description 13
- 230000003093 somatogenic effect Effects 0.000 claims description 12
- KBYRWHFJCBOMBA-UHFFFAOYSA-N n-(2-aminoacetyl)-2-propylpentanamide Chemical compound CCCC(CCC)C(=O)NC(=O)CN KBYRWHFJCBOMBA-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 125000006177 alkyl benzyl group Chemical group 0.000 claims description 5
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 5
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000006277 halobenzyl group Chemical group 0.000 claims description 5
- 125000005059 halophenyl group Chemical group 0.000 claims description 5
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims description 5
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000006502 nitrobenzyl group Chemical group 0.000 claims description 5
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- CBQFYKZIUCLTTM-UHFFFAOYSA-N CCCC(=CCC)C(=O)NC(=O)CN Chemical compound CCCC(=CCC)C(=O)NC(=O)CN CBQFYKZIUCLTTM-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 10
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 125000002946 cyanobenzyl group Chemical group 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 208000004454 Hyperalgesia Diseases 0.000 description 11
- 206010019233 Headaches Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 206010015866 Extravasation Diseases 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 230000036251 extravasation Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 206010053552 allodynia Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229960000604 valproic acid Drugs 0.000 description 4
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 3
- 208000027520 Somatoform disease Diseases 0.000 description 3
- 208000008548 Tension-Type Headache Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 208000027753 pain disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 206010043269 Tension headache Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000452413 Sabra Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003574 anti-allodynic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical group C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22597700P | 2000-08-17 | 2000-08-17 | |
| US22597300P | 2000-08-17 | 2000-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200301427B true ZA200301427B (en) | 2004-02-23 |
Family
ID=26920105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200301427A ZA200301427B (en) | 2000-08-17 | 2003-02-21 | Valproic acid derivatives for the treatment of pain. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20020052418A1 (de) |
| EP (1) | EP1311256B1 (de) |
| JP (1) | JP2004505999A (de) |
| KR (1) | KR100851955B1 (de) |
| CN (1) | CN100462069C (de) |
| AT (1) | ATE301995T1 (de) |
| AU (1) | AU8830801A (de) |
| CA (1) | CA2418455A1 (de) |
| CZ (1) | CZ2004362A3 (de) |
| DE (1) | DE60112766T2 (de) |
| DK (1) | DK1311256T3 (de) |
| ES (1) | ES2245377T3 (de) |
| HU (1) | HUP0401867A2 (de) |
| IL (2) | IL154470A0 (de) |
| MX (1) | MXPA03001458A (de) |
| NO (1) | NO20030724L (de) |
| NZ (1) | NZ524687A (de) |
| PL (1) | PL363041A1 (de) |
| SI (1) | SI1311256T1 (de) |
| WO (1) | WO2002013766A2 (de) |
| ZA (1) | ZA200301427B (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60120104T2 (de) * | 2001-03-20 | 2006-09-21 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz |
| DK1243263T3 (da) * | 2001-03-21 | 2003-03-17 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte |
| US20040175423A1 (en) * | 2003-02-05 | 2004-09-09 | Daniella Licht | Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds |
| US20040176463A1 (en) * | 2003-02-05 | 2004-09-09 | Daniella Licht | Immediate release formulation of n-(2-propylpentanoyl)glycinamide |
| IL157751A0 (en) * | 2003-02-28 | 2004-03-28 | Yissum Res Dev Co | New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them |
| EP1491188A1 (de) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen |
| US20060004098A1 (en) * | 2003-07-28 | 2006-01-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compounds useful for treating neurological disorders |
| JP4664924B2 (ja) * | 2003-12-02 | 2011-04-06 | ウーツェーベー ファルマ ゲーエムベーハー | 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用 |
| US20060009384A1 (en) * | 2003-12-05 | 2006-01-12 | David Rudd | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| EP1579858A1 (de) * | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| AU2005232395B2 (en) | 2004-04-16 | 2010-09-09 | Schwarz Pharma Ag | Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
| EP1604655A1 (de) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| WO2006012603A2 (en) * | 2004-07-22 | 2006-02-02 | Nps Pharmaceuticals, Inc. | Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases |
| EA014055B1 (ru) * | 2004-08-27 | 2010-08-30 | Шварц Фарма Аг | Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами |
| EP1642889A1 (de) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Verbessertes Syntheseschema für Lacosamid |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| EP1754476A1 (de) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| EP1873527A1 (de) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Verfahren zur Identifizierung von CRMP-Modulatoren |
| CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| EA019757B1 (ru) | 2006-06-15 | 2014-06-30 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая композиция с синергетическим противосудорожным эффектом |
| ES2326355B1 (es) * | 2008-02-25 | 2010-08-10 | Centro Atlantico Del Medicamento, S.A. | Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico. |
| KR101733189B1 (ko) * | 2010-10-06 | 2017-05-08 | (주)아모레퍼시픽 | 손톱 또는 발톱 성장 촉진용 조성물 |
| EP2468261A1 (de) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulierung von Lacosamid |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3010599A1 (de) * | 1979-03-22 | 1980-10-09 | Continental Pharma | Derivate von glycinamid, deren herstellung und verwendung |
| US4301176A (en) * | 1980-08-18 | 1981-11-17 | Warner-Lambert Company | Method of administering calcium valproate |
| LU83729A1 (fr) * | 1981-11-04 | 1983-09-01 | Galephar | Sels d'acide valproique,leur preparation et leur utilisation |
| US4913906B1 (en) * | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| US5169642A (en) * | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
| US6287598B1 (en) * | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| US5585358A (en) * | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| WO1997035586A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
| ATE284683T1 (de) * | 1996-08-30 | 2005-01-15 | Nps Pharma Inc | Isovaleramid zur behandlung von schüttelkrämpfen, epilepsie, kopfschmerzen und spastischer lähmung |
| IL121268A0 (en) * | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders |
| US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| MXPA00012808A (es) * | 1998-06-22 | 2002-04-24 | American Biogenetic Sciences | El uso de analogo de acido valproico para tratamiento y prevencion de migrana y enfermedad afectiva. |
| ES2228465T3 (es) * | 1999-01-19 | 2005-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Uso derivados anticonvulsionantes para el tratamiento de cefaleas en brotes. |
-
2001
- 2001-08-17 IL IL15447001A patent/IL154470A0/xx unknown
- 2001-08-17 KR KR1020037002061A patent/KR100851955B1/ko not_active Expired - Fee Related
- 2001-08-17 DK DK01968030T patent/DK1311256T3/da active
- 2001-08-17 ES ES01968030T patent/ES2245377T3/es not_active Expired - Lifetime
- 2001-08-17 EP EP01968030A patent/EP1311256B1/de not_active Expired - Lifetime
- 2001-08-17 HU HU0401867A patent/HUP0401867A2/hu unknown
- 2001-08-17 MX MXPA03001458A patent/MXPA03001458A/es active IP Right Grant
- 2001-08-17 WO PCT/US2001/025919 patent/WO2002013766A2/en not_active Ceased
- 2001-08-17 CA CA002418455A patent/CA2418455A1/en not_active Abandoned
- 2001-08-17 DE DE60112766T patent/DE60112766T2/de not_active Expired - Lifetime
- 2001-08-17 JP JP2002518914A patent/JP2004505999A/ja active Pending
- 2001-08-17 NZ NZ524687A patent/NZ524687A/en unknown
- 2001-08-17 CN CNB018171346A patent/CN100462069C/zh not_active Expired - Fee Related
- 2001-08-17 CZ CZ2004362A patent/CZ2004362A3/cs unknown
- 2001-08-17 PL PL01363041A patent/PL363041A1/xx not_active Application Discontinuation
- 2001-08-17 SI SI200130418T patent/SI1311256T1/sl unknown
- 2001-08-17 AU AU8830801A patent/AU8830801A/xx not_active Withdrawn
- 2001-08-17 AT AT01968030T patent/ATE301995T1/de not_active IP Right Cessation
- 2001-08-17 US US09/932,370 patent/US20020052418A1/en not_active Abandoned
-
2003
- 2003-02-14 NO NO20030724A patent/NO20030724L/no not_active Application Discontinuation
- 2003-02-14 IL IL154470A patent/IL154470A/en not_active IP Right Cessation
- 2003-02-21 ZA ZA200301427A patent/ZA200301427B/en unknown
-
2004
- 2004-04-16 US US10/826,904 patent/US20040204495A1/en not_active Abandoned
-
2009
- 2009-06-24 US US12/457,875 patent/US8288442B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR100851955B1 (ko) | 2008-08-12 |
| ES2245377T3 (es) | 2006-01-01 |
| IL154470A (en) | 2010-11-30 |
| MXPA03001458A (es) | 2004-05-04 |
| JP2004505999A (ja) | 2004-02-26 |
| NZ524687A (en) | 2005-01-28 |
| DE60112766D1 (de) | 2005-09-22 |
| HUP0401867A2 (hu) | 2004-12-28 |
| US20020052418A1 (en) | 2002-05-02 |
| DE60112766T2 (de) | 2006-03-30 |
| NO20030724D0 (no) | 2003-02-14 |
| IL154470A0 (en) | 2003-09-17 |
| CN100462069C (zh) | 2009-02-18 |
| SI1311256T1 (sl) | 2005-12-31 |
| CZ2004362A3 (cs) | 2005-01-12 |
| WO2002013766A2 (en) | 2002-02-21 |
| US20090281045A1 (en) | 2009-11-12 |
| DK1311256T3 (da) | 2005-11-28 |
| EP1311256B1 (de) | 2005-08-17 |
| EP1311256A4 (de) | 2004-03-24 |
| EP1311256A2 (de) | 2003-05-21 |
| WO2002013766A3 (en) | 2002-06-20 |
| AU8830801A (en) | 2002-02-25 |
| CN1551762A (zh) | 2004-12-01 |
| US20040204495A1 (en) | 2004-10-14 |
| US8288442B2 (en) | 2012-10-16 |
| ATE301995T1 (de) | 2005-09-15 |
| NO20030724L (no) | 2003-02-14 |
| KR20030036691A (ko) | 2003-05-09 |
| CA2418455A1 (en) | 2002-02-21 |
| PL363041A1 (en) | 2004-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8288442B2 (en) | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders | |
| HUE033180T2 (en) | Peptide compounds for the treatment of difficult to cure epileptic diseases | |
| KR20070007931A (ko) | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 | |
| JP2008539250A (ja) | アテローム性動脈硬化症を処置するための方法 | |
| US6555585B2 (en) | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder | |
| AU2001288308B2 (en) | Valproic acid derivatives for the treatment of pain | |
| CA2566362C (en) | Treating seizures using ice inhibitors | |
| AU2001288308A1 (en) | Valproic acid derivatives for the treatment of pain | |
| HK1067555A (en) | Valproic acid derivatives for the treatment of pain | |
| KR20240049578A (ko) | 트리카프릴린을 이용한 편두통 및 관련 두통 증상 치료 방법 | |
| HK1166613A (en) | Treating seizures using ice inhibitors |